Jagsonpal Pharmaceuticals profit and loss

Latest FY26

Revenue: ₹287cr+6.9% on FY25
EBITDA: ₹58.1cr+13.7% on FY25
Net profit: ₹43.1cr−22.2% on FY25
EPS: ₹6.40−22.5% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	301	287	269	209	237	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	11.2	12.0	8.2	9.3	5.7
	312	299	277	218	242
	16.5	16.1	18.3	22.1	31.2
	94.1	89.2	80.2	54.0	57.6
	−2.5	−0.9	−2.1	3.9	4.3
	77.9	70.7	70.9	48.5	56.4
	1.0	1.0	1.0	0.8	0.4
	8.5	9.4	8.1	1.7	1.2
	53.4	54.0	50.3	57.2	53.0
	249	240	227	188	204
	61.4	58.1	51.1	23.1	34.2
	52.9	48.6	42.9	21.4	32.9
Profit
	63.1	59.6	50.2	29.9	38.3
	−2.3	−2.1	19.7	0.0	−3.5
	60.8	57.5	69.9	29.9	34.8
	14.4	13.2	13.6	7.6	7.6
	0.9	1.2	0.9	−0.2	0.5
	15.3	14.4	14.5	7.4	8.1
	45.5	43.1	55.4	22.5	26.7
	45.5	43.1	55.4	22.5	26.7
	0.0	0.4	0.2	0.2	−9.4
	45.5	43.4	55.6	22.7	17.4
Per share
	₹6.83	₹6.40	₹8.26	₹8.49	₹10.20
	₹6.71	₹6.31	₹8.22	₹8.46	₹10.20
Revenue detail — as filed
	—	0.0	0.0	0.0	−0.4
Other comprehensive income — detail
	0.0	0.4	0.2	—	—
	0.0	0.5	0.3	0.3	−10.9
	0.0	0.1	0.1	—	—
	—	—	—	0.1	−1.5
Per share — as-filed variants
	₹6.83	₹6.40	₹8.26	₹8.49	₹10.20
	₹6.71	₹6.31	₹8.22	₹8.46	₹10.20
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	193	183	172	129	144
	64.1%	63.7%	64.1%	61.7%	60.7%
Adjusted (ex-exceptional items) — derived
	63.1	59.6	50.2	29.9	38.3
	−2.3	−2.1	19.7	0.0	−3.5
	47.2	44.6	39.8	22.5	29.4
	₹7.09	₹6.63	₹5.93	₹8.49	₹11.21

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

JAGSNPHARM₹230.96

Jagsonpal Pharmaceuticals Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersAMRUTANJAN NGLFINE SYNCOMF HESTERBIO SIGACHI LINCOLN WINDLASMcap ₹1,547 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	236.7	208.7	268.7	287.2	300.8
Other Income	5.7	9.3	8.2	12.0	11.2
Total Income	242.4	218.0	276.9	299.2	312.0
Expenses
+ Cost of Materials Consumed	31.2	22.1	18.3	16.1	16.5
+ Purchases of Stock-in-Trade	57.6	54.0	80.2	89.2	94.1
+ Changes in Inventories	4.3	3.9	-2.1	-0.9	-2.5
+ Employee Benefit Expense	56.4	48.5	70.9	70.7	77.9
+ Finance Costs	0.4	0.8	1.0	1.0	1.0
+ Depreciation & Amortisation	1.2	1.7	8.1	9.4	8.5
+ Other Expenses	53.0	57.2	50.3	54.0	53.4
Total Expenses	204.2	188.1	226.7	239.6	248.9
EBITDA	34.2	23.1	51.1	58.1	61.4
EBIT	32.9	21.4	42.9	48.6	52.9
Profit
PBT before Exceptional Items	38.3	29.9	50.2	59.6	63.1
+ Exceptional Items	-3.5	0.0	19.7	-2.1	-2.3
Pretax Income	34.8	29.9	69.9	57.5	60.8
+ Current Tax	7.6	7.6	13.6	13.2	14.4
+ Deferred Tax	0.5	-0.2	0.9	1.2	0.9
Tax Expense	8.1	7.4	14.5	14.4	15.3
Net Income	26.7	22.5	55.4	43.1	45.5
+ Net Income — Continuing Ops	26.7	22.5	55.4	43.1	45.5
+ Other Comprehensive Income	-9.4	0.2	0.2	0.4	0.0
Total Comprehensive Income	17.4	22.7	55.6	43.4	45.5
Per Share
Basic EPS	10.20	8.49	8.26	6.40	6.83
Diluted EPS	10.20	8.46	8.22	6.31	6.71
Revenue Detail — as filed
+ Share of P&L — Partnership Firms / LLPs	-0.4	0.0	0.0	0.0	—
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	0.2	0.4	0.0
+ Items NOT to be Reclassified to P&L	-10.9	0.3	0.3	0.5	0.0
+ Tax on Items NOT to be Reclassified	—	—	0.1	0.1	0.0
+ Tax on Items NOT to be Reclassified — alt tag	-1.5	0.1	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	10.20	8.49	8.26	6.40	6.83
Diluted EPS — Continuing Operations	10.20	8.46	8.22	6.31	6.71
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	143.6	128.7	172.3	182.9	192.7
Gross Margin %	60.67	61.68	64.11	63.66	64.08
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	38.3	29.9	50.2	59.6	63.1
− Exceptional Items (reconciliation)	-3.5	0.0	19.7	-2.1	-2.3
Net Income Adj (tax-effected)	29.4	22.5	39.8	44.6	47.2
EPS Adj	11.21	8.49	5.93	6.63	7.09
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	5.00	5.00	2.00	2.00	2.00
Paid Up Equity Capital	13.1	13.2	13.3	13.4	13.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.